Overview

A Phase 3 Comparative Study of TAP-144-SR(6M) in Postoperative and Hormone Therapy-naïve Patients With Premenopausal Breast Cancer

Status:
Completed

Trial end date:
2014-12-01

Target enrollment:

Participant gender:

Summary

Hormone dynamics, pharmacokinetics, safety, and efficacy of TAP-144-SR(6M) will be evaluated against TAP-144-SR(3M) in postoperative and hormone therapy-naïve patients with premenopausal breast cancer

Phase:

Phase 3

Details

Lead Sponsor:

Takeda

Treatments:

Leuprolide